Story thread · 2 reports / 2 sources

Leo Pharma Buys Rights to Skin Disease Drug in Latest Deal

bloomberg.com · 4h · first report

How the coverage leans

Across 2 sources · syndicated copies counted once

Leo Pharma A/S agreed to buy the global rights to a drug in late-stage development to treat two rare genetic skin diseases, adding to a series of deals as the Danish drugmaker positions for an initial public offering.

The coverage

  1. Leo Pharma to license Tanabe’s rare disease drug for pain with sun exposure

    endpts.com · 4h

The conversation · 0

Sign in to join the conversation.

No comments yet — start the thread.